— Study meets primary endpoint: ProSavin® is safe, well-tolerated and mediates long-term improvement of motor function — Oxford, UK – 16 April 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”)… Read More
— Study meets primary endpoint: ProSavin® is safe, well-tolerated and mediates long-term improvement of motor function — Oxford, UK – 16 April 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”)… Read More
Click here to download the full 2011 preliminary results statement.Click here to download the 2011 results slide deck.Click here to listen to the… Read More
—Appointment of new Chief Financial Officer and Company Secretary — Oxford, UK – 10 February 2012: Oxford BioMedica (“Oxford BioMedica” or… Read More
— Positive review of all patient cohorts by Data Monitoring Committee —— ProSavin® provides long-term improvement of motor function —… Read More
Oxford, UK – 16 November 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period from 1 July to 15 November 2011. Read More
— Research and development agreement signed with Mayo Clinic — Oxford, UK – 31 October 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the… Read More
— Third ocular product partnered with Sanofi approved to enter clinical development — Oxford, UK – 18 October 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading… Read More
Click here to download the full 2011 interim results statement.Click here to download the 2011 interim results slide deck. Read More
— Positive interim review of fourth patient cohort by Data Monitoring Committee — Oxford, UK – 4 August 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading… Read More
— RetinoStat® Progress in Phase I Study in Wet Age-Related Macular Degeneration Oxford, UK – 22 June 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene therapy… Read More
— ‘In vivo’ diagnostic rights granted for cancer imaging — Oxford, UK – 7 June 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the… Read More